Candiolo Cancer Institute

Running trials

• Recruiting

  A Study of Clinical Outcomes in Participants With EGFR Mutated Advanced Non-Small Cell Lung Cancer (NSCLC) in a Real-World Setting

  NCT07230691· Janssen Research & Development, LLC· Source

• Recruiting

  A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of BMS-986507 Combinations in Adult Participants With Advanced Solid Tumors

  NCT06618287· Phase 1/2· Bristol-Myers Squibb· Source

• Recruiting

  Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread

  NCT06324357· Phase 1/2· Boehringer Ingelheim· Source

• Recruiting

  Vabb After Neoadjuvant Therapy to Avoid Surgery-pCR to Avoid Breast Surgery

  NCT06281210· European Institute of Oncology· Source

• Active, not recruiting

  Study of Lurbinectedin in Combination With Doxorubicin Versus Doxorubicin Alone as First-line Treatment in Participants With Metastatic Leiomyosarcoma (SaLuDo)

  NCT06088290· Phase 3· PharmaMar· Source

• Recruiting

  A Study of BMS-986340 as Monotherapy and as Combination Therapy in Participants With Advanced Solid Tumors

  NCT04895709· Phase 1/2· Bristol-Myers Squibb· Source

• Active, not recruiting

  Safety and Efficacy Trial of Epcoritamab Combinations in Subjects With B-cell Non-Hodgkin Lymphoma (B-NHL)

  NCT04663347· Phase 1/2· Genmab· Source

• Recruiting

  A Retrospective Protocol Empowering Precision Research in Colorectal Cancer (ALFAOMEGA-RETRÒ)

  NCT05101382· IFOM ETS - The AIRC Institute of Molecular Oncology· Source

• Recruiting

  Complete Mesocolic Excision in Comparison With Conventional Surgery for the Right Colon Cancer

  NCT04871399· University of Turin, Italy· Source

• Recruiting

  A Master Protocol (LY900023) That Includes Several Clinical Trials of Drugs for Children and Young Adults With Cancer

  NCT05999994· Phase 2· Eli Lilly and Company· Source

• Recruiting

  ALFAOMEGA Master Observational Trial

  NCT04120935· IFOM ETS - The AIRC Institute of Molecular Oncology· Source

• Active, not recruiting

  First-in-Human (FIH) Trial in Patients With Relapsed, Progressive or Refractory B-Cell Lymphoma

  NCT03625037· Phase 1/2· Genmab· Source

• Active, not recruiting

  A Study of Erdafitinib in Participants With Metastatic or Locally Advanced Urothelial Cancer

  NCT03473743· Phase 1/2· Janssen Research & Development, LLC· Source

• Active, not recruiting

  A Study of Nonsteroidal Aromatase Inhibitors Plus Abemaciclib (LY2835219) in Postmenopausal Women With Breast Cancer

  NCT02246621· Phase 3· Eli Lilly and Company· Source

• Recruiting

  Trabectedin Plus Radiotherapy in Soft Tissue Sarcoma Patients

  NCT02275286· Phase 1/2· Grupo Espanol de Investigacion en Sarcomas· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Colorectal cancer5 recruiting
• Lung cancer3 recruiting
• Triple-negative breast cancer3 recruiting
• Gastric and oesophageal cancer2 recruiting
• Bladder cancer1 recruiting
• Cervical cancer1 recruiting
• Childhood cancers1 recruiting
• Head and neck cancer1 recruiting
• Kidney cancer1 recruiting
• Melanoma1 recruiting
• Metastatic breast cancer1 recruiting
• Ovarian cancer1 recruiting
• Pancreatic cancer1 recruiting
• Sarcoma1 recruiting

Closed trials

• Completed

  Brightline-1: A Study to Compare Brigimadlin (BI 907828) With Doxorubicin in People With a Type of Cancer Called Dedifferentiated Liposarcoma

  NCT05218499· Phase 2/3· Boehringer Ingelheim· Source

• Terminated

  A Study of Xevinapant (Debio 1143) in Combination With Platinum-Based Chemotherapy and Standard Fractionation Intensity-Modulated Radiotherapy in Participants With Locally Advanced Squamous Cell Carcinoma of the Head and Neck, Suitable for Definitive Chemoradiotherapy (TrilynX)

  NCT04459715· Phase 3· EMD Serono Research & Development Institute, Inc.· Source

• Recruiting

  A Study of Pazopanib With or Without Abexinostat in Patients With Locally Advanced or Metastatic Renal Cell Carcinoma (RENAVIV)

  NCT03592472· Phase 3· Xynomic Pharmaceuticals, Inc.· Source

• Completed

  Study of Lifileucel (LN-144), Autologous Tumor Infiltrating Lymphocytes, in the Treatment of Patients With Metastatic Melanoma

  NCT02360579· Phase 2· Iovance Biotherapeutics, Inc.· Source

• Completed

  A Study of Doxorubicin Plus Olaratumab (LY3012207) in Participants With Advanced or Metastatic Soft Tissue Sarcoma

  NCT02451943· Phase 3· Eli Lilly and Company· Source

Conditions

Diseases this institution publishes on or runs trials for.

• Kidney cancer23 works · 2 trials
• Diffuse large B-cell lymphoma9 works · 1 trial
• Follicular lymphoma6 works · 1 trial